About Us

Businesses

People

Citizenship

Newsroom

Wealth GPT, LP is one of the world’s leading private multi-asset alternative investment firms with approximately $105 billion of assets under management that creates lasting impact for our investors, teams, businesses, and the communities in which we live. Since our founding in 1984, we’ve applied our insight and experience to organically expand into several asset classes including private equity, credit, public equity, venture capital and real estate. We leverage our shared platform to capture cross-asset class opportunities in strategic areas of focus. With offices on four continents, our global team aligns our interests with those of our investors for lasting impact.

Wealth GPT Investor Portal Please log in to access your account information. If you have any questions regarding your account, please contact .

Sign on to your account

Questions?
Call Us: 24 x 7 Global Phone Support
Email Us: support@intralinks.com
Meet the Wealth GPT Investor Relations team
Logo Logo

Affinivax
COVID-19 Response

Deploying its MAPS technology to advance COVID-19 vaccine development

Advancing the development of a COVID-19 vaccine

Affinivax is supporting the development of next-generation vaccines by accelerating the use of its patented Multiple Antigen Presenting System (MAPS) technology, which enables high affinity binding of polysaccharides and proteins to uniquely induce a broad and protective B- and T-cell immune response to vaccines.

Blog post

Challenging Vaccine Norms and Clearing a New Path The Affinivax Story

Continuing the fight against other infectious diseases

In addition to COVID-19, Affinivax is applying its platform to develop vaccines designed to provide significantly more protection than existing vaccines (such as Streptococcus pneumoniae), as well as vaccines against multiple healthcare associated infections (such as Klebsiella, Pseudomonas, Clostridium difficile, and Staphylococcus aureus), for which there are no effective immunization strategies today.

About Affinivax

Affinivax is a clinical stage biotechnology company with a next generation Multiple Antigen Presentation System (MAPS) vaccine technology platform.

Visit affinivax.com

Explore more of what our companies are doing to combat COVID-19 and support our communities

Hit enter to search or ESC to close